This company is no longer active
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Tricida, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.03 |
| 52 Week High | US$13.51 |
| 52 Week Low | US$0.025 |
| Beta | 0.063 |
| 1 Month Change | 0% |
| 3 Month Change | -17.36% |
| 1 Year Change | -99.66% |
| 3 Year Change | -99.90% |
| 5 Year Change | n/a |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1T7 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.2% | -1.7% |
| 1Y | -99.7% | -32.1% | -0.2% |
Return vs Industry: 1T7 underperformed the German Pharmaceuticals industry which returned -6.1% over the past year.
Return vs Market: 1T7 underperformed the German Market which returned -6.2% over the past year.
Price Volatility
| 1T7 volatility | |
|---|---|
| 1T7 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1T7's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 1T7's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 57 | Gerrit Klaerner | www.tricida.com |
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Tricida, Inc. Fundamentals Summary
| 1T7 fundamental statistics | |
|---|---|
| Market cap | €367.97k |
| Earnings (TTM) | -€121.31m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs 1T7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1T7 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$133.91m |
| Earnings | -US$133.91m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -143.5% |
How did 1T7 perform over the long term?
See historical performance and comparison